glucagon in retatrutide triple agonist glp-1 gip phase 2 nejm 2023 Medscape Retatrutide for weight loss: Study

They represent a platform therapy with far-reaching potential across some of the most costly, intractable diseases in healthcareand yet, access is moving in the wrong direction

But in the decades since, it became clear that the bodys resistance to leptin made it ineffective as a standalone treatment for most people with obesity

Subsequent research has extended these findings to broader metabolic populations, with some studies reporting reductions of up to 20% in abdominal fat over a 6-month research period

Athletes should be especially careful

Theres no washout period required, and we adjust dosing based on updated lab work at each check-in